Biopharmaceutical News and Research

RSS

Gilead and Yale enter multi-year cancer research collaboration

Gilead Sciences, Inc. and Yale School of Medicine today announced the formation of a multi-year research collaboration focused on the discovery of novel cancer therapies. The research effort will initially span four years with an option to renew for up to ten years.

30 Mar 2011

Researchers develop new drug for multiple cancer treatment

Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug called AT-406 with potential to treat multiple types of cancer.

30 Mar 2011

Cephalon intends to make takeover bid for ChemGenex

Cephalon, Inc. and ChemGenex Pharmaceuticals Limited today jointly announced that Cephalon's wholly-owned subsidiary, Cephalon CXS Holdings Pty Ltd, intends to make a takeover bid for ChemGenex.

29 Mar 2011

CytRx to present bafetinib preclinical study results at AACR Annual Meeting

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that results from a series of preclinical studies demonstrating that its oncology drug candidate bafetinib inhibits bone destruction in model systems is being presented on April 2, 2011 at the American Academy for Cancer Research 102nd Annual Meeting in Orlando, Florida.

29 Mar 2011

Anergis SA closes funding round for allergy vaccines

Anergis SA announced today that it has closed a Series A financing round raising CHF 18 millions from European biotech funds and private local investors.

28 Mar 2011

Almac extends Pharma Services business unit to increase demand for storage capacity

In response to increased client demand for cold and dedicated frozen storage capacity for biopharmaceuticals, Almac's Pharma Services business unit has expanded its commercial facilities to include an additional 6124 sq ft of cold and frozen storage.

25 Mar 2011

Boehringer Ingelheim formally acquires Amgen's Fremont manufacturing site

Today Boehringer Ingelheim formally acquired Amgen's biopharmaceutical development and manufacturing facility in Fremont, California. This acquisition involves leasing buildings, acquiring physical equipment and assuming manufacturing processes done at the Fremont site.

25 Mar 2011

Perceptive Informatics announces eClinical Product Suite survey results

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation, today announced results of a survey conducted during its recent webinar entitled "Designing and Delivering an eClinical Product Suite."

From Parexel 24 Mar 2011

Aptiv Solutions, Cancer Genetics partner to deliver comprehensive solutions for clinical trials in oncology

Aptiv Solutions and Cancer Genetics, Inc. (CGI) have formed a strategic partnership focused on delivering comprehensive solutions to biopharmaceutical and medical device firms conducting clinical trials for oncology therapeutics.

24 Mar 2011

KaloBios commences KB004 Phase 1 trial in patients with leukemia

KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced treatment of the first patient in a Phase 1 clinical trial of KB004, its first-in-class Humaneered™ monoclonal antibody, in EphA3-expressing hematologic malignancies.

24 Mar 2011

Positive data from Omeros' OMS302 Phase 2b trial in patients undergoing cataract surgery

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today reported positive data from a Phase 2b clinical trial evaluating OMS302 in patients undergoing cataract surgery.

23 Mar 2011

Positive results from TheraVida THVD-201 Phase 1 trial in patients with OAB, UUI

TheraVida, Inc., a clinical stage biopharmaceutical company developing novel combination drug products, today presented positive results from a Phase 1 clinical trial of its lead product candidate THVD-201 for the treatment of overactive bladder and urge urinary incontinence.

23 Mar 2011

Shire's Replagal and VPRIV data on Gaucher and Fabry patients presented at ACMG meeting

Shire plc, the global specialty biopharmaceutical company, presented new data for Replagal in patients with Fabry disease, and VPRIV in patients with type 1 Gaucher disease, at the 2011 American College of Medical Genetics' Annual Clinical Genetics Meeting, held in Vancouver, BC, from March 16-20, 2011.

22 Mar 2011

Ventirx VTX-1463 positive clinical data against allergic rhinitis presented at AAAAI meeting

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists and antagonists for the treatment of cancer, respiratory and autoimmune diseases, announced today the presentation of positive clinical results from its randomized, placebo-controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis.

22 Mar 2011

FDA accepts Arisaph's ARI-3037MO IND for phase I human clinical trial

Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted the Company's recently submitted Investigational New Drug application to evaluate ARI-3037MO in a phase I human clinical trial in healthy volunteers.

22 Mar 2011

Cephalon to acquire Gemin X Pharmaceuticals

Cephalon, Inc. announced today that it has signed a definitive merger agreement under which it will acquire all of the outstanding capital stock of Gemin X Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing first-in-class cancer therapeutics, for $225 million cash on a cash-free, debt-free basis. Gemin X stockholders could also receive up to $300 million in cash payments upon the achievement of certain regulatory and sales milestones.

22 Mar 2011

China PharmaHub, University of California enter license agreement for stem cell universal donor blood product

China PharmaHub Corp., a biopharmaceutical acquisition and development company, today announced that it has signed a exclusive worldwide license agreement with the University of California, for worldwide rights to develop, commercialize and market a universal donor blood product derived from embryonic stem cells developed by UCSD Associate Professor of Medicine and Pediatrics Dr. Ewa Carrier.

21 Mar 2011

Insmed regains compliance with NASDAQ minimum bid price rule

Insmed Incorporated, a biopharmaceutical company, today announced that it has received notification from The NASDAQ Stock Market that it has regained compliance with the minimum $1.00 per share bid price requirement.

21 Mar 2011

Synageva BioPharma closes $25 million private equity financing

Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, announced today the closing of a $25 million private equity financing.

21 Mar 2011

FDA clears Insmed IND for ARIKACE Phase 3 clinical trial in nontuberculous mycobacteria lung infections

Insmed Incorporated, a biopharmaceutical company, announced today that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of ARIKACE™ (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung infections has been cleared by the U.S. Food and Drug Administration (FDA).

21 Mar 2011

Biopharmaceutical News and Research

Gilead and Yale enter multi-year cancer research collaboration

Researchers develop new drug for multiple cancer treatment

Cephalon intends to make takeover bid for ChemGenex

CytRx to present bafetinib preclinical study results at AACR Annual Meeting

Anergis SA closes funding round for allergy vaccines

Almac extends Pharma Services business unit to increase demand for storage capacity

Boehringer Ingelheim formally acquires Amgen's Fremont manufacturing site

Perceptive Informatics announces eClinical Product Suite survey results

Aptiv Solutions, Cancer Genetics partner to deliver comprehensive solutions for clinical trials in oncology

KaloBios commences KB004 Phase 1 trial in patients with leukemia

Positive data from Omeros' OMS302 Phase 2b trial in patients undergoing cataract surgery

Positive results from TheraVida THVD-201 Phase 1 trial in patients with OAB, UUI

Shire's Replagal and VPRIV data on Gaucher and Fabry patients presented at ACMG meeting

Ventirx VTX-1463 positive clinical data against allergic rhinitis presented at AAAAI meeting

FDA accepts Arisaph's ARI-3037MO IND for phase I human clinical trial

Cephalon to acquire Gemin X Pharmaceuticals

China PharmaHub, University of California enter license agreement for stem cell universal donor blood product

Insmed regains compliance with NASDAQ minimum bid price rule

Synageva BioPharma closes $25 million private equity financing

FDA clears Insmed IND for ARIKACE Phase 3 clinical trial in nontuberculous mycobacteria lung infections

Pittcon Highlights: Pharmaceutical & Biologic eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News